Dalpiciclib after surgery for HR-positive, HER2-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a pill called Dalpiciclib given after surgery to help prevent early-stage breast cancer from coming back. It is for women with hormone receptor-positive (HR+) and HER2-negative breast cancer that has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- Your breast cancer is HR-positive and HER2-negative (based on lab tests of your tumor)
- Your cancer was stage II or III and was removed by surgery within the past 12 months
- You have recovered from any side effects of prior chemotherapy or radiation (except hair loss or mild nerve issues)
- Your overall health is good (ECOG score 0 or 1, meaning you are fully active or only need rest for light activity)
- Your blood counts, liver, and kidney function are within safe limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.